Investigating how a specific RNA affects glioblastoma's resistance to chemotherapy
Examining the Role of a Novel Long Noncoding RNA, linc02454, in Resistance of Glioblastoma to Temozolomide
This study is looking at a specific part of the genetic code that might help glioblastoma, a tough brain tumor, resist treatment with a common chemotherapy drug, and by understanding this better, the researchers hope to find new ways to make the treatment work better for patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10907540 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor that often recurs despite treatment with temozolomide, radiation, and surgery. The study aims to understand the role of a long noncoding RNA called linc02454 in mediating resistance to this chemotherapy. By examining how linc02454 interacts with other genes, particularly the CXCR4 gene, the researchers hope to uncover new strategies to enhance the effectiveness of temozolomide in treating glioblastoma. Patients may benefit from insights that could lead to improved treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing treatment with temozolomide.
Not a fit: Patients with other types of brain tumors or those who are not receiving temozolomide may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting long noncoding RNAs to improve cancer treatment outcomes, suggesting potential success for this approach.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Attenello, Frank — University of Southern California
- Study coordinator: Attenello, Frank
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.